HTA43 Assessing the added value of fixed-dose combinations in non-communicable diseases: a comparative HTA analysis across Canada, Scotland, France, and Germany (2014-2024)

Alani, Ahmad Hecham ORCID: 0000-0001-6318-3017, Mills, Mackenzie and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2025) HTA43 Assessing the added value of fixed-dose combinations in non-communicable diseases: a comparative HTA analysis across Canada, Scotland, France, and Germany (2014-2024). Value in Health, 28 (6, Supplement 1). S254. ISSN 1098-3015

Full text not available from this repository.

Abstract

To examine factors influencing approval and reimbursement of fixed-dose combinations (FDCs) for non-communicable diseases (NCDs) across four HTA agencies (SMC, HAS, G-BA, CDA) from 2014-2024. The analysis covered clinical and economic evidence, stakeholder perspectives, and implementation factors for FDCs targeting diabetes mellitus (DM), asthma, chronic obstructive pulmonary disease (COPD), and cardiovascular diseases (CVDs).

Item Type:	Article
Additional Information:	© 2025 Published by Elsevier Inc.
Divisions:	Health Policy
Subjects:	R Medicine > RA Public aspects of medicine R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	17 Jul 2025 10:27
Last Modified:	17 Jul 2025 10:27
URI:	http://eprints.lse.ac.uk/id/eprint/128861

Actions (login required)

View Item